Loading…
Loading…
B. Braun Melsungen AG is a German family-owned medical technology group (founded 1839, Melsungen, Hesse) spanning IV/infusion therapy and pump systems, dialysis machines (B. Braun Avitum), and — through its Aesculap division — surgical instruments, implants, and sterilization technology.
No parent_slug set -- B. Braun SE and B. Braun Holding GmbH & Co. KG are private holding entities with no dossier of their own in this corpus (they are not operating companies with their own material exposure). This is a well-documented family-controlled group (Braun family, 6th generation under CEO Anna Maria Braun since 2019), not widely held or state/PE-owned.
Named counterparties identified by open-source research and written only where a primary source states the relationship — never inferred from sector or co-mention. 1 customer-side. This is a partial view: it covers the relationships we could evidence, not the company's full supply base.
B. Braun Medical Ltd supplies a branded IV sedative to the NHS under an NHS England framework agreement; confirmed in a 2025-02 VPAG dispute-resolution panel decision (GOV.UK) covering B. Braun's pandemic-era off-contract sales dispute.
Scope. Absence of a counterparty here is not evidence that none exists — most commercial sourcing is confidential and never becomes public. Rows without a share figure mean no share was disclosed, not that the relationship is small.
Every exposure is read as a buyer dependency; the top 2 are its binding chokepoints.
As a buyer, policy pressure across its consumed materials is rising.
Descriptive trend in official policy actions on this company’s materials — a policy-pressure trend, not a price or trading signal. No forward probability is implied. Direction is measured on actions we have discovered, and discovery lags events: where the recent window is too thin to support a calm reading, the row says coverage-limited instead of easing.
No actions in the register have named or swept this company in the last 24 months.